Novartis returns for another piece of IFM Therapeutics

13 Mar 2024

License out/inAcquisition

After buying a portion of IFM Therapeutics’ pipeline in 2019, Novartis is back for a second helping as it bags its STING antagonists. The Swiss Big Pharma had paid $90 million upfront a few years ago for an option and collaboration agreement and would pay up to $745 million in milestones if it opted to acquire IFM’s subsidiary IFM Due. Its time is due, and the companies said Wednesday that Novartis will have full rights to IFM Due’s portfolio of STING antagonists, which could turn into treatments for inflammation-driven diseases. The deal is a result of a four-year preclinical tie-up on small molecules.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Novartis AG

IFM Therapeutics LLC

IFM Independent Fund Management AG

Indications

Inflammation

Targets

STING

Drugs

STING antagonists(Merck)SX-RDS1

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.